![General Commons Logo](./assets/images/crdc-logo.svg) 
## Example Layout Pages) 
-------------------------- 
[Table Example](./demopage-table.md)  
[Text Example](./demopage-text.md)  
[NCI Logo](./demopage-table-NCILogo.md)  
[caNano Logo](./demopage-table-caNanoLogo.md)  
[General Commons Logo](./demopage-table-GCLogo.md) \
[Test HTML Page](./testDOI.html)
# caNanoLab DOI Repository 
-------------------------- 
This repository contains the DOI landing pages for the caNanoLab project. 
 
## DOI Pages 
-------------------------- 
| File Name | File Type | DOI | 
|----------|---------|---------|  
| [NIST - NCL Joint Assay Protocol, PCC-10](./29949954.md) | Protocol | Not Available | 
| [NEU-MAmiji - Video Protocol on Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using EGFR-targeted Gelatin Nanoparticles](./40108033.md) | Protocol | Not Available | 
| [UTSA-ZKereselidze - Video Protocol on Gold Nanostar Synthesis with a Silver Seed Mediated Growth Method](./40108034.md) | Protocol | Not Available | 
| [VAMC-JDouglas - Video Protocol on Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis](./40108035.md) | Protocol | Not Available | 
| [UWO-CFCho - Video Protocol on Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging](./40108036.md) | Protocol | Not Available | 
| [CWRU-AWen - Video Protocol on Viral Nanoparticles for In vivo Tumor Imaging](./40108037.md) | Protocol | Not Available | 
| [CU-AHughes - Video Protocol on Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples](./40108038.md) | Protocol | Not Available | 
| [USC-JYHwang - Video Protocol on Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors](./40108039.md) | Protocol | Not Available | 
| [TU-SAhmadian - Video Protocol on Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay](./40108040.md) | Protocol | Not Available | 
| [Large Scale Purification of RNA Nanoparticles by Preparative Ultracentrifugation](./57802752.md) | Protocol | Not Available | 
| [Simple Method for Constructing RNA Triangle, Square, Pentagon by Tuning Interior RNA 3WJ Angle from 60 to 90 or 108 degrees](./57802753.md) | Protocol | Not Available | 
| [Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.](./57802754.md) | Protocol | Not Available | 
| [Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast, and Gynecologic Malignancies](./62226432.md) | Protocol | Not Available | 
| [PET Imaging of Patients with Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGD Silica Nanomolecular Particle Tracer: A Microdosing Study](./62226433.md) | Protocol | Not Available | 
| [NCL Method ITA-2.2](./62947328.md) | Protocol | Not Available | 
| [Density Measurement](./69763072.md) | Protocol | Not Available | 
| [Zeta Potential measurement](./70385664.md) | Protocol | Not Available | 
| [Crystallite size XRD](./70385665.md) | Protocol | Not Available | 
| [Particle Size with Nitrogen Adsorption and BET analysis](./70385677.md) | Protocol | Not Available | 
| [Organic and Elemental Carbon (EC-OC) analysis](./70385678.md) | Protocol | Not Available | 
| [FTIR analysis](./70385689.md) | Protocol | Not Available | 
| [Trace metals analysis with ICP-MS](./70385696.md) | Protocol | Not Available | 
| [X-Ray Photoelectron Spectroscopy ](./70385697.md) | Protocol | Not Available | 
| [Transmission Electron Microscopy - Shape assessment](./70385698.md) | Protocol | Not Available | 
| [Particle Size (Feret diameter) - TEM](./70385699.md) | Protocol | Not Available | 
| [Primary Particle Size (Feret) Distribution - TEM](./70385700.md) | Protocol | Not Available | 
| [Crystal Structure with X-ray diffraction ](./70385701.md) | Protocol | Not Available | 
| [Endotoxin Assessment (rFC)](./70385719.md) | Protocol | Not Available | 
| [WHO sterility test](./70385720.md) | Protocol | Not Available | 
| [Porosity with Liquid Nitrogen Adsorption ](./70385721.md) | Protocol | Not Available | 
| [Stoichiometry - molecular weight (X-ray spectroscopy)](./70385722.md) | Protocol | Not Available | 
| [Stoichiometry Molecular weight - ICPMS](./70385723.md) | Protocol | Not Available | 
| [Critical Delivered Sonication Energy - DLS](./70385724.md) | Protocol | Not Available | 
| [Effective Density-VCM method](./70385725.md) | Protocol | Not Available | 
| [Size Distribution of the Suspension - DLS](./70385726.md) | Protocol | Not Available | 
| [Specific conductance-DLS](./70385727.md) | Protocol | Not Available | 
| [Specific Surface Area](./70385728.md) | Protocol | Not Available | 
| [SEM Imaging and Image Analysis](./70549504.md) | Protocol | Not Available | 
| [Radiolabeling of Alpha MSH-PEG-Cy5-Cdots for PET-CT Imaging](./78610440.md) | Protocol | Not Available | 
| [Zirconium 89 Radiolabeling of DFO-scFv-PEG-Cy5-Cornell Dots ](./78610441.md) | Protocol | Not Available | 
| [Synthesis of DFO-ScFV-PEG-Cy5-Cornell Dots](./78610442.md) | Protocol | Not Available | 
| [NCL Method STE-1.4](./84475910.md) | Protocol | Not Available | 
| [NCL Method PCC-2: Measuring Zeta Potential of Nanoparticles](./88539136.md) | Protocol | 10.17917/ZB8P-FB40  | 
| [NCL Method PCC-16: Quantitation of PEG on PEGylated Gold Nanoparticles Using Reversed Phase High Performance Liquid Chromatography and Charged Aerosol Detection](./88539138.md) | Protocol | 10.17917/1VHC-MJ13  | 
| [NCL Method PCC-18: Quantitation of APIs in Polymeric Prodrug Formulations](./88539139.md) | Protocol | 10.17917/JM45-VA25 | 
| [NCL Method PCC-19: Asymmetric-Flow Field-Flow Fractionation](./88539140.md) | Protocol | 10.17917/8S1D-BN17  | 
| [NCL Method PCC-17: Quantitation of Nanoparticle Composition Using Thermogravimetric Analysis](./88539141.md) | Protocol | 10.17917/WF0H-1V72  | 
| [NCL Method ITA-1: Analysis of Hemolytic Properties of Nanoparticles](./88539142.md) | Protocol | 10.17917/V9AP-D094  | 
| [NCL Method ITA-2.1: Analysis of Platelet Aggregation by Cell Counting](./88539143.md) | Protocol | 10.17917/0165-RC67  | 
| [NCL Method ITA-2.2: Analysis of Platelet Aggregation by Light Transmission Aggregometry](./88539144.md) | Protocol | 10.17917/7GEJ-8G77 | 
| [NCL Method ITA-3: Mouse Granulocyte-Macrophage Colony-Forming Unit Assay](./88539145.md) | Protocol | 10.17917/YTHD-KF51 | 
| [NCL Method ITA-4: Analysis of Nanoparticle Interaction with Plasma Proteins by 2D PAGE](./88539146.md) | Protocol | 10.17917/822G-S949  | 
| [NCL Method ITA-5.1: Qualitative Analysis of Total Complement Activation by Western Blot](./88539147.md) | Protocol | 10.17917/HA0Q-5B49 | 
| [NCL Method ITA-5.2: Analysis of Complement Activation by Single-Plex EIA or Multiplex ELISA](./88539148.md) | Protocol | 10.17917/EQCT-3C51 | 
| [NCL Method ITA-6.1: Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)](./88539149.md) | Protocol | 10.17917/C8XW-BQ05 | 
| [Supplement to NIST-NCL Joint Assay Protocols PCC-8 & PCC-9: Metal Quantitation by Inductively Coupled Plasma-Mass Spectrometry](./88834048.md) | Protocol | 10.17917/B68Q-T959 | 
| [NCL Method ITA-6.2: Leukocyte Proliferation Assay (Immunostimulation)](./88834054.md) | Protocol | 10.17917/WBSK-2W04  | 
| [NCL Method IEA-1: Analysis of Nanoparticle Effects on Invasion of Cancer Cells](./88834056.md) | Protocol | 10.17917/GS4C-N171 | 
| [NCL Method ITA-6.3: Leukocyte Proliferation Assay (Immunosuppression)](./88834057.md) | Protocol | 10.17917/M173-MY22   | 
| [NCL Method ITA-8.2: Analysis of Nanoparticle Chemoattractant Properties Using Label-Free, Real-Time Chemotaxis Assay](./88834059.md) | Protocol | 10.17917/QENR-XG24 | 
| [NCL Method ITA-8.1: Chemotaxis Assay](./88834060.md) | Protocol | 10.17917/CPWX-SP39 | 
| [NCL Method ITA-9.1: Phagocytosis Assay](./88834061.md) | Protocol | 10.17917/ZTXV-XC08 | 
| [NCL Method ITA-9.2: In Vitro Assay for Assessing Nanoparticle Effects on Monocyte/Macrophage Phagocytic Function](./88834062.md) | Protocol | 10.17917/WZGC-DG48 | 
| [NCL Method ITA-10: Preparation of Human Whole Blood and Peripheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro](./88834063.md) | Protocol | 10.17917/GBQR-BN14 | 
| [NCL Method ITA-18: Human Lymphocyte Activation (HuLa) Assay for Analysis of Immunosuppressive Properties of Nanomaterials](./88834064.md) | Protocol | 10.17917/416C-5429  | 
| [NCL Method ITA-12: In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time](./88834065.md) | Protocol | 10.17917/7SF3-7A88 | 
| [NCL Method ITA-17: Analysis of Nanoparticle Effects on Leukocyte Procoagulant Activity](./88834066.md) | Protocol | 10.17917/ZQ6R-KD69  | 
| [NCL Method ITA-11: Measurement of Nanoparticle Effects on Cytotoxic Activity of NK Cells by Label-Free RT-CES System](./88834067.md) | Protocol | 10.17917/GMXG-BH29 | 
| [NCL Method ITA-23: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-1Œ? in Culture Supernatants](./88834068.md) | Protocol | 10.17917/RD78-BZ75 | 
| [NCL Method ITA-24: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human TNFŒ± in Culture Supernatants](./88834069.md) | Protocol | 10.17917/JQM0-0G48 | 
| [NCL Method ITA-22: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-8 in Culture Supernatants](./88834070.md) | Protocol | 10.17917/SJT2-7P72 | 
| [NCL Method ITA-25: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IFNŒ? in Culture Supernatants](./88834071.md) | Protocol | 10.17917/DM9W-8430  | 
| [In Vitro Toxicology Assay Kit, Lactic Dehydrogenase based ](./89751552.md) | Protocol | Not Available | 
| [CellTiter 96 AQueous One Solution Cell Proliferation Assay](./89751553.md) | Protocol | Not Available | 
| [NCL Method ITA-27: Multiplex Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human Cytokines in Culture Supernatants](./100335618.md) | Protocol | 10.17917/P2T3-8P84 | 
| [NCL Method STE-2.2: Detection of Bacterial Contamination Using Luria Broth Agar Plates](./110788608.md) | Protocol | 10.17917/30CJ-2J27  | 
| [Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations](./110788609.md) | Protocol | Not Available | 
| [Elemental Analysis in Biological Matrices Using ICP-MS](./110788610.md) | Protocol | Not Available | 
| [PEG Quantitation Using Reversed-Phase High-Performance Liquid Chromatography and Charged Aerosol Detection](./110788611.md) | Protocol | Not Available | 
| [Designing an In Vivo Efficacy Study of Nanomedicines for Preclinical Tumor Growth Inhibition](./110788612.md) | Protocol | Not Available | 
| [Quantitation of Surface Coating on Nanoparticles Using Thermogravimetric Analysis](./110788613.md) | Protocol | Not Available | 
| [Updated Method for In Vitro Analysis of Nanoparticle Hemolytic Properties](./110788614.md) | Protocol | Not Available | 
| [In Vitro Assessment of Nanoparticle Effects on Blood Coagulation](./110788615.md) | Protocol | Not Available | 
| [In Vitro Analysis of Nanoparticle Effects on the Zymosan Uptake by Phagocytic Cells](./110788616.md) | Protocol | Not Available | 
| [Assessing NLRP3 Inflammasome Activation by Nanoparticles, in Characterization of nanoparticles intended for drug delivery](./110788617.md) | Protocol | Not Available | 
| [Analysis of Complement Activation by Nanoparticles](./110788618.md) | Protocol | Not Available | 
| [Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo](./110788619.md) | Protocol | Not Available | 
| [Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles](./110788620.md) | Protocol | Not Available | 
| [Analysis of Nanoparticle-Adjuvant Properties In Vivo](./110788621.md) | Protocol | Not Available | 
| [In Vitro and In Vivo Methods for Analysis of Nanoparticle Potential to Induce Delayed-Type Hypersensitivity Reactions](./110788622.md) | Protocol | Not Available | 
| [Autophagy Monitoring Assay II: Imaging Autophagy Induction in LLC-PK1 Cells Using GFP-LC3 Protein Fusion Construct](./110788623.md) | Protocol | Not Available | 
| [Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer](./110788624.md) | Protocol | Not Available | 
| [Measuring the Hydrodynamic Size of Nanoparticles in Aqueous Media Using Batch-Mode Dynamic Light Scattering](./112852992.md) | Protocol | Not Available | 
| [Characterization of Nanoparticles by Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry](./112852993.md) | Protocol | Not Available | 
| [Zeta Potential Measurement](./112852994.md) | Protocol | Not Available | 
| [Biological Tissue and Cell Culture Specimen Preparation for TEM Nanoparticle Characterization](./112852995.md) | Protocol | Not Available | 
| [SEM X-Ray Microanalysis of Nanoparticles Present in Tissue or Cultured Cell Thin Sections](./112852996.md) | Protocol | Not Available | 
| [Detecting and Measuring Free Gadolinium in Nanoparticles for MRI Imaging](./112852997.md) | Protocol | Not Available | 
| [Lipid Component Quantitation by Thin Layer Chromatography](./112852998.md) | Protocol | Not Available | 
| [Detection and Quantitative Evaluation of Endotoxin Contamination in Nanoparticle Formulations by LAL-Based Assays](./112852999.md) | Protocol | Not Available | 
| [NCL Method STE-2.1: Detection of Microbial Contamination Using Millipore Sampler Devices](./112853000.md) | Protocol | 10.17917/DVJF-SS25  | 
| [Gold Nanoparticle Quantitation via Fluorescence in Solution and Cell Culture](./112853002.md) | Protocol | Not Available | 
| [Evaluation of Cytotoxicity of Nanoparticulate Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells](./112853003.md) | Protocol | Not Available | 
| [Monitoring Nanoparticle-Treated Hepatocarcinoma Cells for Apoptosis](./112853004.md) | Protocol | Not Available | 
| [Detecting Reactive Oxygen Species in Primary Hepatocytes Treated with Nanoparticles](./112853005.md) | Protocol | Not Available | 
| [Assay to Detect Lipid Peroxidation upon Exposure to Nanoparticles](./112853006.md) | Protocol | Not Available | 
| [Monitoring Glutathione Homeostasis in Nanoparticle-Treated Hepatocytes](./112853008.md) | Protocol | Not Available | 
| [Autophagy Monitoring Assay: Qualitative Analysis of MAP LC3-I to II Conversion by Immunoblot](./112853009.md) | Protocol | Not Available | 
| [Monitoring Lysosomal Activity in Nanoparticle-Treated Cells](./112853010.md) | Protocol | Not Available | 
| [Method for Analysis of Nanoparticle Hemolytic Properties In Vitro](./112853011.md) | Protocol | Not Available | 
| [Method for In Vitro Analysis of Nanoparticle Thrombogenic Properties](./112853012.md) | Protocol | Not Available | 
| [Qualitative Analysis of Total Complement Activation by Nanoparticles](./112853013.md) | Protocol | Not Available | 
| [Method for Analysis of Nanoparticle Effects on Cellular Chemotaxis](./112853014.md) | Protocol | Not Available | 
| [In Vitro Analysis of Nanoparticle Uptake by Macrophages Using Chemiluminescence](./112853015.md) | Protocol | Not Available | 
| [NCL Method STE-2.3: Detection of Bacterial Contamination Using Tryptic Soy Broth Agar Plates](./114130946.md) | Protocol | 10.17917/WFT5-1J52  | 
| [NCL Method STE-2.4: Detection of Bacterial Contamination using Tryptic Soy Agar Plates and RPMI Suspension Tests for the Purposes of Determining Bacterial ID](./114130947.md) | Protocol | 10.17917/86Y9-3Y16  | 
| [Endotoxin and Depyrogenation Tips](./114130949.md) | Protocol | 10.17917/G780-R621 | 
| [NCL Method PCC-21: Measuring Size and Number Concentration of Metallic Nanoparticles using SP-ICP-MS](./114130950.md) | Protocol | 10.17917/SCP8-6P58 | 
| [NCL Method PCC-22: Residual Organic Solvent Analysis in Nanoformulations Using Headspace Gas Chromatography](./114130951.md) | Protocol | 10.17917/QFEP-HD46 | 
| [NCL Method PCC-20: Particle Concentration and Size using the Spectradyne nCS1](./114130952.md) | Protocol | 10.17917/7Z55-SJ80 | 
| [Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate (LAL) Assays](./114130953.md) | Protocol | Not Available | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Liposomal Products](./114130954.md) | Protocol | 10.17917/B5N6-F154 | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Colloidal Metal Nanoparticles](./114130955.md) | Protocol | 10.17917/2MYC-DE76 | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Polymeric Nanoparticles](./114130956.md) | Protocol | 10.17917/G13J-XR95 | 
| [Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics and Toxicology](./114130957.md) | Protocol | 10.17917/W63A-GR02  | 
| [NCL Method ITA-36: Detection of Naturally Occurring Antibodies to PEG and PEGylated Liposomes in Plasma of Human Donor Volunteers](./114130958.md) | Protocol | 10.17917/PBZB-N042  | 
| [NCL Method ITA-29: Detection of Nanoparticles' Ability to Stimulate Toll-Like Receptors Using HEK-Blue Reporter Cell Lines](./114130959.md) | Protocol |  10.17917/EYQD-3T61  | 
| [NCL Method ITA-37.1: Immunophenotyping‚ÄîInstrument Calibration and Reagent Qualification for Immunophenotyping Analysis of Human Peripheral Blood Mononuclear Cell Cultures](./114130960.md) | Protocol | 10.17917/C7K01C | 
| [NCL Method ITA-37.2: Immunophenotyping‚ÄîAnalysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells](./114130961.md) | Protocol | 10.17917/C7KW2Q  | 
| [NCL Method ITA-40: Understanding the Role of Scavenger Receptor A1 in Nanoparticle Uptake by Murine Macrophages](./114130962.md) | Protocol | 10.17917/0J6M-EJ19  | 
| [NCL Method STE-4: Detection of Œ?-glucan contamination](./114130963.md) | Protocol | 10.17917/BA6D-TE29 | 
| [CD34+ CD90+ Digital Magnetic Cell Sorting Assay](./114130964.md) | Protocol | Not Available | 
| [CPMV-S100A9 Vaccination and Antibody Titers](./114130966.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Vaccination and Antibody Titers](./114130967.md) | Protocol | Not Available | 
| [CPMV-S100A9 Production](./114130968.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Production Protocol](./114130969.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Tumor Metastasis Assays](./114130970.md) | Protocol | Not Available | 
| [CPMV-S100A9 Agarose Gel Electrophoresis Protocol](./114130973.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Agarose Gel Electrophoresis Protocol](./114130974.md) | Protocol | Not Available | 
| [Qbeta-S100A9 DLS Protocol](./114130975.md) | Protocol | Not Available | 
| [Qbeta-S100A9 FPLC Protocol](./114130976.md) | Protocol | Not Available | 
| [Qbeta-S100A9 SDS-PAGE Protocol](./114130977.md) | Protocol | Not Available | 
| [Qbeta-S100A9 TEM Protocol](./114130978.md) | Protocol | Not Available | 
| [CPMV-S100A9 DLS Protocol](./114130979.md) | Protocol | Not Available | 
| [CPMV-S100A9 SDS-PAGE Protocol](./114130981.md) | Protocol | Not Available | 
| [CPMV-S100A9 TEM Protocol](./114130982.md) | Protocol | Not Available | 
| [CPMV-S100A9 UV-VIS Protocol](./114130983.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Lung Cytokine Quantitation Protocol](./114130984.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Lung MDSC Quantitation Protocol](./114130985.md) | Protocol | Not Available | 
| [Qbeta-S100A9 Lung Bacterial Load](./114130986.md) | Protocol | Not Available | 
| [CPMV-S100A9 Lung Metastasis Model Protocol](./114130987.md) | Protocol | Not Available | 
| [NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations](./114130988.md) | Protocol | 10.17917/PHFP-8573  | 
| [NCL Method STE-1.4: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Chromogenic LAL Assay](./114130989.md) | Protocol | 10.17917/B6HB-C950  | 
| [NCL Method STE-1.3: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Gel-Clot LAL Assay](./114130990.md) | Protocol | 10.17917/VRHF-5Y74  | 
| [NCL Method STE-1.2: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Turbidity LAL Assay](./114130991.md) | Protocol | 10.17917/RK6R-P820  | 
| [NCL Method STE-1.1: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the End Point Chromogenic LAL Assay](./114130992.md) | Protocol | 10.17917/5WSQ-7X78 | 
| [NIST-NCL Joint Assay Protocol, PCC-1: Measuring the Size of Nanoparticles in Aqueous Media Using Batch-Mode Dynamic Light Scattering](./114130993.md) | Protocol | 10.17917/3F5S-6728 | 
| [NIST-NCL Joint Assay Protocol, PCC-6: Size Measurement of Nanoparticles Using Atomic Force Microscopy](./114130994.md) | Protocol | 10.17917/DHAG-PC35 | 
| [NIST-NCL Joint Assay Protocol, PCC-7: Measuring the Size of Nanoparticles Using Transmission Electron Microscopy (TEM)](./114130995.md) | Protocol | 10.17917/C7N7-N938 | 
| [NIST-NCL Joint Assay Protocol, PCC-8: Determination of Gold in Rat Tissue with Inductively Coupled Plasma Mass Spectrometry](./114130996.md) | Protocol | 10.17917/SA6R-9D63 | 
| [NIST-NCL Joint Assay Protocol, PCC-9: Determination of Gold in Rat Blood with Inductively Coupled Plasma Mass Spectrometry](./114130997.md) | Protocol | 10.17917/3THH-7C14 | 
| [NIST-NCL Joint Assay Protocol, PCC-10: Analysis of Gold Nanoparticles by Electrospray Differential Mobility Analysis (ES-DMA)](./114130998.md) | Protocol | 10.17917/0QDS-ZT72 | 
| [NIST-NCL Joint Assay Protocol, PCC-11: Method for Determination of the Mass Fraction of Particle-Bound Gold in Suspensions of Gold Nanoparticles](./114130999.md) | Protocol | 10.17917/2ZKD-6321 | 
| [NIST-NCL Joint Assay Protocol, PCC-12: Measuring the Electrolytic Conductivity of Nanoparticle Suspensions](./114131000.md) | Protocol | 10.17917/9Q5G-G245 | 
| [NIST-NCL Joint Assay Protocol, PCC-13: Measuring the pH of Nanoparticle Suspensions](./114131001.md) | Protocol | 10.17917/YNXM-AD40 | 
| [NIST-NCL Joint Assay Protocol, PCC-15: Measuring the Size of Colloidal Gold Nano-particles using HighResolution Scanning Electron Microscopy](./114131002.md) | Protocol | 10.17917/NHEE-7838 | 
| [NIST-NCL Joint Assay Protocol, PCC-14: Quantification of Free and Chelated Gadolinium Species in Nanoemulsion-Based Magnetic Resonance Imaging Contrast Agent Formulations](./114131003.md) | Protocol | 10.17917/X6PD-WC14 | 
| [NCL Method PCC-23: Quantitation of Residual DMSO in Nanoformulations Using Gas Chromatography with Direct Injection and Flame Ionization Detection](./114131004.md) | Protocol | 10.17917/C75P4P | 
| [NCL Method PHA-1: Radioactive Blood Partitioning Assay](./114131005.md) | Protocol | 10.17917/2HFK-9E25  | 
| [NCL Method PHA-2: Ultrafiltration Drug Release Assay Utilizing a Stable Isotope Tracer](./114131006.md) | Protocol | 10.17917/8EJ1-9P65 | 
| [NCL Method GTA-1: LLC-PK1 Kidney Cytotoxicity Assay](./114131007.md) | Protocol | 10.17917/Q6EC-XC97  | 
| [NCL Method GTA-2: Hep G2 Hepatocarcinoma Cytotoxicity Assay](./114131008.md) | Protocol | 10.17917/96Z2-NZ61 | 
| [NCL Method GTA-3: Hep G2 Hepatocyte Glutathione Assay](./114131009.md) | Protocol |  10.17917/EHR9-HB86  | 
| [NCL Method GTA-4: Hep G2 Hepatocyte Lipid Peroxidation Assay](./114131010.md) | Protocol | 10.17917/H65D-SJ70 | 
| [NCL Method GTA-5: LLC-PK1 Kidney Cell Apoptosis Assay](./114131011.md) | Protocol | 10.17917/E9YS-N327  | 
| [NCL Method GTA-6: HepG2 Hepatocarcinoma Apoptosis Assay](./114131012.md) | Protocol | 10.17917/3F7T-M688  | 
| [NCL Method GTA-7: Hepatocyte Primary ROS Assay](./114131013.md) | Protocol | 10.17917/0WF6-GX40  | 
| [NCL Method GTA-11: Autophagic Dysfunction Assay‚ÄîQualitative Analysis of MAP LC3-I to LC3-II Conversion by Western Blot](./114131014.md) | Protocol | 10.17917/WY7Z-MD10 | 
| [NCL Method GTA-12: Autophagic Dysfunction in LLC-PK1 Cells](./114131015.md) | Protocol | 10.17917/YPTH-N396  | 
| [NCL Method GTA-14: Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay](./114131016.md) | Protocol | 10.17917/95VC-ZP26 | 
| [NCL Method ITA-7: Detection of Nitric Oxide Production by the Macrophage Cell Line RAW264.7](./114131017.md) | Protocol | 10.17917/T6JC-ZG30  | 
| [NCL Method ITA-14: Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro](./114131018.md) | Protocol | 10.17917/0YC3-6793 | 
| [NCL Method ITA-26: Detection of Intracellular Complement Activation in Human T Lymphocytes](./114131019.md) | Protocol | 10.17917/Y4CQ-SV79 | 
| [NCL Method ITA-31: Detection of Nanoparticle-Mediated Total Oxidative Stress in T Cells Using CM-H2DC-FDA Dye](./114131020.md) | Protocol | 10.17917/PRQZ-3095 | 
| [NCL Method ITA-32: Detection of Mitochondrial Oxidative Stress in T Cells Using MitoSOX Red Dye](./114131021.md) | Protocol | 10.17917/HWV7-3E78 | 
| [NCL Method ITA-33: Detection of Changes in Mitochondrial Membrane Potential in T Cells Using JC-1 Dye](./114131022.md) | Protocol | 10.17917/RTMF-4853 | 
| [NCL Method ITA-34: Detection of Antigen Presentation by Murine Bone Marrow-Derived Dendritic Cells](./114131023.md) | Protocol | 10.17917/YTEJ-F575 | 
| [NCL Method ITA-35: Antigen-Specific Stimulation of CD8+ T Cells by Murine Bone Marrow-Derived Dendritic Cells](./114131024.md) | Protocol | 10.17917/1QRB-NC62 | 
| [Size Measurement of Nanoparticles Using Atomic Force Microscopy](./114131025.md) | Protocol | Not Available | 
| [Analysis of Microbial Contamination in Nanoparticle Formulations](./114131026.md) | Protocol | Not Available | 
| [Quantitation of Nanoparticles in Serum Matrix by Capillary Electrophoresis](./114131027.md) | Protocol | Not Available | 
| [Detection of Bacterial Contamination in Nanoparticle Formulations by Agar Plate Test](./114131028.md) | Protocol | Not Available | 
| [Immunoelectron Microscopy for Visualization of Nanoparticles](./114131029.md) | Protocol | Not Available | 
| [Imaging of Liposomes by Transmission Electron Microscopy](./114131030.md) | Protocol | Not Available | 
| [Nanoparticle Size Distribution and Stability Assessment Using Asymmetric-Flow Field-Flow Fractionation](./114131031.md) | Protocol | Not Available | 
| [Assessment of Protein Binding Using Asymmetric-Flow Field-Flow Fractionation Combined with Multi-angle Light Scattering and Dynamic Light Scattering](./114131032.md) | Protocol | Not Available | 
| [Quantitation of Active Pharmaceutical Ingredients in Polymeric Drug Products Using Elemental Analysis](./114131033.md) | Protocol | Not Available | 
| [Particle Size and Concentration Measurement Using the Spectradyne nCS1 Instrument](./114131034.md) | Protocol | Not Available | 
| [Measuring Size and Number Concentration of Metallic Nanoparticles Using spICP-MS](./114131035.md) | Protocol | Not Available | 
| [Ion Quantitation in Liposomal Products Using RP-HPLC with Charged Aerosol Detection](./114131036.md) | Protocol | Not Available | 
| [A Static Headspace Gas Chromatography Method for Quantitation of Residual Solvents in Nanoformulations](./114131037.md) | Protocol | Not Available | 
| [Current Considerations and Practical Solutions for Overcoming Nanoparticle Interference with LAL Assays and Minimizing Endotoxin Contamination](./114131038.md) | Protocol | Not Available | 
| [Detection of Beta-Glucan Contamination in Nanoparticle Formulations](./114131039.md) | Protocol | Not Available | 
| [Detection of Intracellular Complement Activation by Nanoparticles in Human T Lymphocytes](./114131040.md) | Protocol | Not Available | 
| [Analysis of Nanoparticles‚Äô Potential to Induce Autoimmunity](./114131041.md) | Protocol | Not Available | 
| [Analysis of Nanoparticles‚Äô Effects on Drug-Induced Psoriasis](./114131042.md) | Protocol | Not Available | 
| [Detection of Nanoparticle-Mediated Total Oxidative Stress in T Cells Using CM-H2DCFDA Dye](./114131043.md) | Protocol | Not Available | 
| [Detection of Induction of Mitochondrial Oxidative Stress by Nanoparticles in T Cells Using MitoSOX Red Dye](./114131044.md) | Protocol | Not Available | 
| [Detection of Nanoparticle-Mediated Change in Mitochondrial Membrane Potential in T Cells Using JC-1 Dye](./114131045.md) | Protocol | Not Available | 
| [Detection of Antigen Presentation by Murine Bone Marrow‚ÄìDerived Dendritic Cells After Treatment with Nanoparticles](./114131046.md) | Protocol | Not Available | 
| [Antigen-Specific Stimulation of CD8+ T Cells by Murine Bone Marrow‚ÄìDerived Dendritic Cells After Treatment with Nanoparticles](./114131047.md) | Protocol | Not Available | 
| [Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum](./114131048.md) | Protocol | Not Available | 
| [In Vitro and In Vivo Methods for Analysis of Nanoparticles' Potential to Induce Delayed-Type Hypersensitivity Reactions](./114131049.md) | Protocol | Not Available | 
| [Analysis of Nanoparticle Adjuvant Properties](./114131050.md) | Protocol | Not Available | 
| [Methods for Analysis of Nanoparticle Immunosuppressive Properties](./114131051.md) | Protocol | Not Available | 
| [Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model](./114131052.md) | Protocol | Not Available | 
| [Immunophenotyping, Part I: Instrument Calibration and Reagent Qualification for Immunophenotyping Analysis of Human Peripheral Blood Mononuclear Cell Cultures](./114131053.md) | Protocol | Not Available | 
| [Immunophenotyping, Part II: Analysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells](./114131054.md) | Protocol | Not Available | 
| [Understanding the Role of Scavenger Receptor A1 in Nanoparticle Uptake by Murine Macrophages](./114131055.md) | Protocol | Not Available | 
| [Assessment of Temperature-Dependent Drug Release of Solubilizing Nanoformulations Using the SITUA](./114131056.md) | Protocol | Not Available | 
| [Evaluation of Nanomedicine Tissue Distribution and Stability by Alexa Fluor 488 and PEG Immunohistochemistry](./114131057.md) | Protocol | Not Available | 
| [NCL Video Protocol: Dynamic Light Scattering](./114131058.md) | Protocol | Not Available | 
| [NCL Method STE-1.1: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the End Point Chromogenic LAL Assay](./114131059.md) | Protocol | 10.17917/A20K-T950 | 
| [NCL Method STE-1.3: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Gel-Clot LAL Assay](./114131060.md) | Protocol | 10.17917/VZ9M-8351 | 
| [NCL Method STE-1.4: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Chromogenic LAL Assay](./114131061.md) | Protocol | 10.17917/MQJP-YG07 | 
| [NCL Method STE-2.1: Detection of Microbial Contamination Using Millipore Sampler Devices](./114131062.md) | Protocol | 10.17917/P9TT-MN30 | 
| [NCL Method STE-2.2: Detection of Bacterial Contamination Using Luria Broth Agar Plates](./114131063.md) | Protocol | 10.17917/5JCE-HQ72 | 
| [NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations](./114131064.md) | Protocol | 10.17917/QCFR-6F07 | 
| [Endotoxin and Depyrogenation Tips](./114131065.md) | Protocol | 10.17917/916B-JQ80 | 
| [NCL Method STE-1.2: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Turbidity LAL Assay](./114131066.md) | Protocol | 10.17917/54TK-DG93 | 
| [NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations](./114131067.md) | Protocol | 10.17917/XCBE-2712 | 
| [NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations](./114131068.md) | Protocol | 10.17917/R1XZ-X580 | 
| [Endotoxin and Depyrogenation Tips](./114131069.md) | Protocol | 10.17917/8XN0-3373 | 
| [NCL Method PCC-2: Measuring Zeta Potential of Nanoparticles](./114131070.md) | Protocol | 10.17917/71WC-AN25 | 
| [NCL Method PCC-2: Measuring Zeta Potential of Nanoparticles](./114131071.md) | Protocol | 10.17917/NF9V-MM03 | 
| [Supplement to NIST-NCL Joint Assay Protocols PCC-8 & PCC-9: Metal Quantitation by Inductively Coupled Plasma-Mass Spectrometry](./114131072.md) | Protocol | 10.17917/MP68-WN76 | 
| [NCL Method PCC-16: Quantitation of PEG on PEGylated Gold Nanoparticles Using Reversed Phase High Performance Liquid Chromatography and Charged Aerosol Detection](./114131073.md) | Protocol | 10.17917/Y597-RM86 | 
| [NCL Method PCC-17: Quantitation of Nanoparticle Composition Using Thermogravimetric Analysis](./114131074.md) | Protocol | 10.17917/QATM-6Q97 | 
| [NCL Method PCC-18: Quantitation of APIs in Polymeric Prodrug Formulations](./114131075.md) | Protocol | 10.17917/5NNX-F760 | 
| [NCL Method PCC-19: Asymmetric-Flow Field-Flow Fractionation](./114131076.md) | Protocol | 10.17917/RW1F-4D43 | 
| [NCL Method PCC-20: Particle Concentration and Size using the Spectradyne nCS1](./114131077.md) | Protocol | 10.17917/XQ3B-W012 | 
| [NCL Method ITA-1: Analysis of Hemolytic Properties of Nanoparticles](./114131078.md) | Protocol | 10.17917/K0XB-3581 | 
| [NCL Method ITA-1: Analysis of Hemolytic Properties of Nanoparticles](./114131079.md) | Protocol | 10.17917/XJ16-D110 | 
| [NCL Method ITA-2.1: Analysis of Platelet Aggregation by Cell Counting](./114131080.md) | Protocol | 10.17917/MK26-YD70 | 
| [NCL Method ITA-2.1: Analysis of Platelet Aggregation by Cell Counting](./114131081.md) | Protocol | 10.17917/1GSW-5N64 | 
| [NCL Method ITA-2.2: Analysis of Platelet Aggregation by Light Transmission Aggregometry](./114131082.md) | Protocol | 10.17917/2MDV-2445 | 
| [NCL Method ITA-2.2: Analysis of Platelet Aggregation by Light Transmission Aggregometry](./114131083.md) | Protocol | 10.17917/W9YH-YJ13 | 
| [NCL Method ITA-3: Mouse Granulocyte-Macrophage Colony-Forming Unit Assay](./114131084.md) | Protocol | 10.17917/DQZP-7M50 | 
| [NCL Method ITA-3: Mouse Granulocyte-Macrophage Colony-Forming Unit Assay](./114131085.md) | Protocol | 10.17917/0ZHD-SA93 | 
| [NCL Method ITA-4: Analysis of Nanoparticle Interaction with Plasma Proteins by 2D PAGE](./114131086.md) | Protocol | 10.17917/4G01-8T87 | 
| [NCL Method ITA-4: Analysis of Nanoparticle Interaction with Plasma Proteins by 2D PAGE](./114131087.md) | Protocol | 10.17917/3DE3-3446 | 
| [NCL Method ITA-5.1: Qualitative Analysis of Total Complement Activation by Western Blot](./114131088.md) | Protocol | 10.17917/D0GG-4X14 | 
| [NCL Method ITA-5.1: Qualitative Analysis of Total Complement Activation by Western Blot](./114131089.md) | Protocol | 10.17917/6J6H-3R27 | 
| [NCL Method ITA-5.2: Analysis of Complement Activation by Single-Plex EIA or Multiplex ELISA](./114131090.md) | Protocol | 10.17917/WRWV-CW04 | 
| [NCL Method ITA-6: Leukocyte Proliferation Assay](./114131091.md) | Protocol | 10.17917/4VDA-ZS32 | 
| [NCL Method ITA-6.1: Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)](./114131092.md) | Protocol | 10.17917/SX37-3D76 | 
| [NCL Method ITA-6.2: Leukocyte Proliferation Assay (Immunostimulation)](./114131093.md) | Protocol | 10.17917/NB97-6E21 | 
| [NCL Method ITA-6.3: Leukocyte Proliferation Assay (Immunosuppression)](./114131094.md) | Protocol | 10.17917/X2P6-HA51 | 
| [NCL Method ITA-7: Detection of Nitric Oxide Production by the Macrophage Cell Line RAW264.7](./114131095.md) | Protocol | 10.17917/Q94Q-6B29 | 
| [NCL Method ITA-8: Chemotaxis Assay](./114131096.md) | Protocol | 10.17917/W604-T506 | 
| [NCL Method ITA-8.1: Chemotaxis Assay](./114131097.md) | Protocol | 10.17917/K08Q-Y828 | 
| [NCL Method ITA-8.2: Analysis of Nanoparticle Chemoattractant Properties Using Label-Free, Real-Time Chemotaxis Assay](./114131098.md) | Protocol | 10.17917/CFBS-5C02 | 
| [NCL Method ITA-9: Phagocytosis Assay](./114131099.md) | Protocol | 10.17917/NQK3-2449 | 
| [NCL Method ITA-9.1: Phagocytosis Assay](./114131100.md) | Protocol | 10.17917/P4YG-Z672 | 
| [NCL Method ITA-9.2: In Vitro Assay for Assessing Nanoparticle Effects on Monocyte/Macrophage Phagocytic Function](./114131101.md) | Protocol | 10.17917/RXJ2-EG43 | 
| [NCL Method ITA-10: Preparation of Human Whole Blood and Peripheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro](./114131102.md) | Protocol | 10.17917/HVEG-VH85 | 
| [NCL Method ITA-11: Measurement of Nanoparticle Effects on Cytotoxic Activity of NK Cells by Label-Free RT-CES System](./114131103.md) | Protocol | 10.17917/F4CE-FT82 | 
| [NCL Method ITA-11: Measurement of Nanoparticle Effects on Cytotoxic Activity of NK Cells by Label-Free RT-CES System](./114131104.md) | Protocol | 10.17917/2DT9-XS67 | 
| [NCL Method ITA-12: In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time](./114131105.md) | Protocol | 10.17917/P6SK-3R71 | 
| [NCL Method ITA-12: In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time](./114131106.md) | Protocol | 10.17917/GV9W-FF90 | 
| [NCL Method ITA-14: Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro](./114131107.md) | Protocol | 10.17917/72F3-8Z52 | 
| [NCL Method ITA-14: Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro](./114131108.md) | Protocol | 10.17917/AJ1Z-2E64 | 
| [NCL Method ITA-17: Analysis of Nanoparticle Effects on Leukocyte Procoagulant Activity](./114131109.md) | Protocol | 10.17917/NK3Y-2F88 | 
| [NCL Method ITA-17: Analysis of Nanoparticle Effects on Leukocyte Procoagulant Activity](./114131110.md) | Protocol | 10.17917/F32N-3W57 | 
| [NCL Method ITA-18: Human Lymphocyte Activation (HuLa) Assay for Analysis of Immunosuppressive Properties of Nanomaterials](./114131111.md) | Protocol | 10.17917/C59D-T717 | 
| [NCL Method ITA-18: Human Lymphocyte Activation (HuLa) Assay for Analysis of Immunosuppressive Properties of Nanomaterials](./114131112.md) | Protocol | 10.17917/3429-7641 | 
| [NCL Method ITA-22: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-8 in Culture Supernatants](./114131113.md) | Protocol | 10.17917/DKY3-BZ13 | 
| [NCL Method ITA-22: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-8 in Culture Supernatants](./114131114.md) | Protocol | 10.17917/EWMJ-D959 | 
| [NCL Method ITA-23: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-1Œ? in Culture Supernatants](./114131115.md) | Protocol | 10.17917/PQVY-GN53 | 
| [NCL Method ITA-23: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IL-1Œ? in Culture Supernatants](./114131116.md) | Protocol | 10.17917/BHQ7-GD40 | 
| [NCL Method ITA-24: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human TNFŒ± in Culture Supernatants](./114131117.md) | Protocol | 10.17917/X900-GP60 | 
| [NCL Method ITA-24: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human TNFŒ± in Culture Supernatants](./114131118.md) | Protocol | 10.17917/S3CM-4J74 | 
| [NCL Method ITA-25: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IFNŒ? in Culture Supernatants](./114131119.md) | Protocol | 10.17917/ZXVG-DA66 | 
| [NCL Method ITA-25: Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human IFNŒ? in Culture Supernatants](./114131120.md) | Protocol | 10.17917/ZNS7-4E84 | 
| [NCL Method ITA-27: Multiplex Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Human Cytokines in Culture Supernatants](./114131121.md) | Protocol | 10.17917/D4XK-WH24 | 
| [NCL Method ITA-29: Detection of Nanoparticles' Ability to Stimulate Toll-Like Receptors Using HEK-Blue Reporter Cell Lines](./114131122.md) | Protocol | 10.17917/E65B-GP64 | 
| [NCL Method ITA-36: Detection of Naturally Occurring Antibodies to PEG and PEGylated Liposomes in Plasma of Human Donor Volunteers](./114131123.md) | Protocol | 10.17917/06V6-WD77 | 
| [NCL Method ITA-36: Detection of Naturally Occurring Antibodies to PEG and PEGylated Liposomes in Plasma of Human Donor Volunteers](./114131124.md) | Protocol | 10.17917/1RPW-X912 | 
| [NCL Method ITA-37.1: Immunophenotyping‚ÄîInstrument Calibration and Reagent Qualification for Immunophenotyping Analysis of Human Peripheral Blood Mononuclear Cell Cultures](./114131125.md) | Protocol | 10.17917/GJ0C-JY85 | 
| [NCL Method ITA-37.1: Immunophenotyping‚ÄîInstrument Calibration and Reagent Qualification for Immunophenotyping Analysis of Human Peripheral Blood Mononuclear Cell Cultures](./114131126.md) | Protocol | 10.17917/8FKW-D647 | 
| [NCL Method ITA-37.2: Immunophenotyping‚ÄîAnalysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells](./114131127.md) | Protocol | 10.17917/8BPC-VN29 | 
| [NCL Method ITA-37.2: Immunophenotyping‚ÄîAnalysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells](./114131128.md) | Protocol | 10.17917/SGVV-N363 | 
| [NCL Method ITA-40: Understanding the Role of Scavenger Receptor A1 in Nanoparticle Uptake by Murine Macrophages](./114131129.md) | Protocol | 10.17917/NG6J-WH37 | 
| [NCL Method IEA-1: Analysis of Nanoparticle Effects on Invasion of Cancer Cells](./114131130.md) | Protocol | 10.17917/WPJB-EE02 | 
| [NCL Method GTA-1: LLC-PK1 Kidney Cytotoxicity Assay](./114131131.md) | Protocol | 10.17917/5S8G-WB35 | 
| [NCL Method GTA-1: LLC-PK1 Kidney Cytotoxicity Assay](./114131132.md) | Protocol | 10.17917/WV7C-JG27 | 
| [NCL Method GTA-2: Hep G2 Hepatocarcinoma Cytotoxicity Assay](./114131133.md) | Protocol | 10.17917/BFZH-QN35 | 
| [NCL Method GTA-3: Hep G2 Hepatocyte Glutathione Assay](./114131134.md) | Protocol | 10.17917/DWFK-8B95 | 
| [NCL Method GTA-4: Hep G2 Hepatocyte Lipid Peroxidation Assay](./114131135.md) | Protocol | 10.17917/NGR4-KR46 | 
| [NCL Method GTA-5: LLC-PK1 Kidney Cell Apoptosis Assay](./114131136.md) | Protocol | 10.17917/J2HN-5116 | 
| [NCL Method GTA-6: HepG2 Hepatocarcinoma Apoptosis Assay](./114131137.md) | Protocol | 10.17917/RJYY-4562 | 
| [NCL Method GTA-7: Hepatocyte Primary ROS Assay](./114131138.md) | Protocol | 10.17917/PP52-SF51 | 
| [NCL Method GTA-11: Autophagic Dysfunction Assay‚ÄîQualitative Analysis of MAP LC3-I to LC3-II Conversion by Western Blot](./114131139.md) | Protocol | 10.17917/BAWN-K053 | 
| [NCL Method GTA-12: Autophagic Dysfunction in LLC-PK1 Cells](./114131140.md) | Protocol | 10.17917/F3HK-FC87 | 
| [NCL Method GTA-13: In Vitro Blood Partitioning Assay](./114131141.md) | Protocol | 10.17917/ZMDT-FP49 | 
| [NCL Method GTA-14: Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay](./114131142.md) | Protocol | 10.17917/BPA7-XK19 | 
| [NCL Method PHA-1: Radioactive Blood Partitioning Assay](./114131143.md) | Protocol | 10.17917/P2B0-5211 | 
| [NCL Method PHA-2: Ultrafiltration Drug Release Assay Utilizing a Stable Isotope Tracer](./114131144.md) | Protocol | 10.17917/97H6-ZZ07 | 
| [Plasmid Design (pCMV-T7-CPMVRNA2)](./114131145.md) | Protocol | Not Available | 
| [NCL Method STE-1.1: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the End Point Chromogenic LAL Assay](./114131146.md) | Protocol | 10.17917/0DFX-GC30 | 
| [NCL Method STE-1.4: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Chromogenic LAL Assay](./114131147.md) | Protocol | 10.17917/6KEP-3R19 | 
| [NCL Method STE-1.3: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Gel-Clot LAL Assay](./114131148.md) | Protocol | 10.17917/373S-6W98 | 
| [NCL Method STE-1.2: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Turbidity LAL Assay](./114131149.md) | Protocol | 10.17917/2EEV-MY50 | 
| [NIST-NCL Joint Assay Protocol, PCC-11: Method for Determination of the Mass Fraction of Particle-Bound Gold in Suspensions of Gold Nanoparticles](./114131150.md) | Protocol | 10.17917/C73S3Q | 
| [NCL Method PCC-17: Quantitation of Nanoparticle Composition Using Thermogravimetric Analysis](./114131151.md) | Protocol | 10.17917/C73W2C  | 
| [NCL Method PCC-20: Particle Concentration and Size using the Spectradyne nCS1](./114131152.md) | Protocol | 10.17917/C74D4M | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Liposomal Products](./114131153.md) | Protocol | 10.17917/C7201Q | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Colloidal Metal Nanoparticles](./114131154.md) | Protocol | 10.17917/C73011 | 
| [Parameters, Methods, and Considerations for the Physicochemical Characterization of Polymeric Nanoparticles](./114131155.md) | Protocol | 10.17917/C76P40 | 
| [NCL Method ITA-4: Analysis of Nanoparticle Interaction with Plasma Proteins by 2D PAGE](./114131156.md) | Protocol | 10.17917/GS4R-4H02 | 
| [NCL Method ITA-5.1: Qualitative Analysis of Total Complement Activation by Western Blot](./114131157.md) | Protocol | 10.17917/NZYM-3K29 | 
| [NCL Method ITA-6.1: Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)](./114131158.md) | Protocol | 10.17917/PJNB-JJ95 | 
| [NCL Method ITA-6.2: Leukocyte Proliferation Assay (Immunostimulation)](./114131159.md) | Protocol | 10.17917/C70013 | 
| [NCL Method ITA-6.3: Leukocyte Proliferation Assay (Immunosuppression)](./114131160.md) | Protocol | 10.17917/C7059V | 
| [NCL Method ITA-10: Preparation of Human Whole Blood and Peripheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro](./114131161.md) | Protocol | 10.17917/C7G596 | 
| [NCL Method ITA-18: Human Lymphocyte Activation (HuLa) Assay for Analysis of Immunosuppressive Properties of Nanomaterials](./114131162.md) | Protocol | 10.17917/C7J012 | 
| [NCL Method GTA-2: Hep G2 Hepatocarcinoma Cytotoxicity Assay](./114131163.md) | Protocol | 10.17917/C7BC78 | 
| [NCL Method GTA-11: Autophagic Dysfunction Assay‚ÄîQualitative Analysis of MAP LC3-I to LC3-II Conversion by Western Blot](./114131164.md) | Protocol | 10.17917/C77P49 | 
| [Endotoxin and Depyrogenation Guide](./114131165.md) | Protocol | 10.17917/C7PP4B  | 
| [NCL Method ITA-38: Analysis of Nanoparticle Effects on IgE-Dependent Mast Cell Degranulation ](./114131166.md) | Protocol | 10.17917/C7NP41 | 
| [NCL Method ITA-10: Preparation of Human Whole Blood and Peripheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro](./114131167.md) | Protocol | 10.17917/BND8-T188 | 
| [NCL Method ITA-38: Analysis of Nanoparticle Effects on IgE-Dependent Mast Cell Degranulation ](./114131168.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 Production](./114131169.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 Agarose Gel Electrophoresis](./114131170.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 DLS](./114131172.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 SDS-PAGE](./114131173.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 TEM](./114131174.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 In Vivo Efficacy Studies](./114131175.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 Antibody Assays](./114131176.md) | Protocol | Not Available | 
| [CPMV-CH401 & QŒ?-CH401 Cytokine Assays](./114131177.md) | Protocol | Not Available | 
| [Purified CPMV Agarose Gel Electrophoresis Protocol](./114131179.md) | Protocol | Not Available | 
| [Purified CPMV SDS-PAGE Protocol](./114131180.md) | Protocol | Not Available | 
| [Purified CPMV Dynamic Light Scattering (DLS) Protocol](./114131181.md) | Protocol | Not Available | 
| [Purified CPMV Fast Protein Liquid Chromatography (FPLC) Protocol](./114131182.md) | Protocol | Not Available | 
| [Purified CPMV Transmission Electron Microscopy (TEM) Protocol ](./114131183.md) | Protocol | Not Available | 
| [Purified CPMV UV-Vis Protocol](./114131184.md) | Protocol | Not Available | 
| [B16F10 tumor inoculation and intratumoral treatment](./114131185.md) | Protocol | Not Available | 
| [Purified CPMV Cytokine Assay Protocol](./114131186.md) | Protocol | Not Available | 
| [A20 Lymphoma Tumor Model Protocol](./114131187.md) | Protocol | Not Available | 
| [CPMV Mass spectrometry analysis](./114131188.md) | Protocol | Not Available | 
| [CPMV propagation](./114131189.md) | Protocol | Not Available | 
| [Flow cytometry CPMV detection](./114131190.md) | Protocol | Not Available | 
| [RNA Fluorescent in situ Hybridization multiplexed with Immunofluorescence](./114131191.md) | Protocol | Not Available | 
| [RT-PCR for CPMV RNA detection](./114131192.md) | Protocol | Not Available | 
| [ELISpot Protocol](./114131193.md) | Protocol | Not Available | 
| [Western Blot and dot blot for CPMV](./114131194.md) | Protocol | Not Available | 
| [Immunofluorescence Staining Assay Protocol](./114131195.md) | Protocol | Not Available | 
| [Flow Cytometry for Cy5-CPMV and Cy5-PVX](./114131196.md) | Protocol | Not Available | 
| [NCL Method ITA-9.2: In Vitro Assay for Assessing Nanoparticle Effects on Monocyte/Macrophage Phagocytic Function](./114131197.md) | Protocol | 10.17917/WZGC-DG48 | 
